Cardiovascular

PCSK9 Inhibitors

Cardiovascular

Mark this drug class

Examples

alirocumabevolocumab

Prefix / Suffix: -cumab

Physiology

LDL receptors remove cholesterol from the blood. PCSK9 breaks down these receptors. Inhibiting PCSK9 increases LDL removal.

Mechanism of Action

They inhibit PCSK9, increasing LDL receptor availability and lowering LDL cholesterol levels.

Indications

  • Hyperlipidemia
  • Patients not controlled on statins

Side Effects / Adverse Effects

  • Injection site reactions (subcutaneous administration)
  • Flu-like symptoms
  • Nasopharyngitis

Contraindications

  • Hypersensitivity

Nursing Considerations

  • Administer subcutaneously (correct route is essential)
  • Store in refrigerator (maintains drug stability)
  • Monitor LDL levels (assesses effectiveness)
  • Use in patients not responding to statins (common exam scenario)

Ask PharmPal Nurse

Your AI tutor for PCSK9 Inhibitors

Ask me anything about this drug class.

Disclaimer: PharmPal Nurse is for education only and is not medical advice. Do not use it to diagnose, treat, prescribe, or make patient-care decisions; always verify with current drug references, your instructor, facility policy, and a licensed provider. In emergencies, call local emergency services.